{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+product+vehicle&page=4",
    "query": {
      "intervention": "Drug product vehicle",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 354,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+product+vehicle&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+product+vehicle&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T16:32:57.854Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04909450",
      "title": "Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neurotrophic Keratitis"
      ],
      "interventions": [
        {
          "name": "CSB-001 Ophthalmic Solution 0.1%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vehicle Control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Claris Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2021-08-24",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 45,
      "location_summary": "Cave Creek, Arizona • Loma Linda, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Cave Creek",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909450"
    },
    {
      "nct_id": "NCT00306800",
      "title": "Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Photodynamic therapy with methyl aminolevulinate cream",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2007-09",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 7,
      "location_summary": "St. Petersburg, Florida • New York, New York • Rochester, New York + 4 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00306800"
    },
    {
      "nct_id": "NCT01597401",
      "title": "A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Aes-103",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-05-12",
      "completion_date": "2013-06-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597401"
    },
    {
      "nct_id": "NCT03573401",
      "title": "Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Superficial Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biofrontera Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 187,
      "start_date": "2018-09-25",
      "completion_date": "2029-02",
      "has_results": true,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03573401"
    },
    {
      "nct_id": "NCT03088605",
      "title": "Safety and Efficacy of TOP1630 for Dry Eye Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "TOP1630 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo to TOP1630 Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2017-02-20",
      "completion_date": "2017-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-02-14",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088605"
    },
    {
      "nct_id": "NCT04203342",
      "title": "A Therapeutic Equivalence Study of Ketoconazole Cream 2%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tinea Pedis"
      ],
      "interventions": [
        {
          "name": "Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)",
          "type": "DRUG"
        },
        {
          "name": "Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Douglas Pharmaceuticals America Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 682,
      "start_date": "2019-12-11",
      "completion_date": "2020-07-13",
      "has_results": false,
      "last_update_posted_date": "2020-08-06",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 2,
      "location_summary": "Brandon, Florida • Tampa, Florida",
      "locations": [
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04203342"
    },
    {
      "nct_id": "NCT04541108",
      "title": "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Volrustomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabestomig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD9592 + Rilvegostomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Volrustomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Sabestomig",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AZD9592 + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Presage Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-26",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 9,
      "location_summary": "Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541108"
    },
    {
      "nct_id": "NCT00296491",
      "title": "Study Of Allergic Rhinitis In Patients Who Also Have Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "fluticasone propionate/salmeterol (FSC)",
          "type": "DRUG"
        },
        {
          "name": "montelukast (MON)",
          "type": "DRUG"
        },
        {
          "name": "fluticasone propionate (FP)",
          "type": "DRUG"
        },
        {
          "name": "placebo nasal",
          "type": "DRUG"
        },
        {
          "name": "ADVAIR DISKUS",
          "type": "DRUG"
        },
        {
          "name": "placebo capsule",
          "type": "DRUG"
        },
        {
          "name": "placebo DISKUS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 725,
      "start_date": "2005-09",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 104,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 88 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00296491"
    },
    {
      "nct_id": "NCT05263921",
      "title": "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioavailability"
      ],
      "interventions": [
        {
          "name": "PF-07321332/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-03-10",
      "completion_date": "2022-05-19",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05263921"
    },
    {
      "nct_id": "NCT04883593",
      "title": "A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tinea Pedis"
      ],
      "interventions": [
        {
          "name": "TA103",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2020-09-03",
      "completion_date": "2021-02-20",
      "has_results": false,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-10-12T16:32:57.854Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883593"
    }
  ]
}